Search

Displaying results 7951 - 7960 of 10000 in total
  1. Drug

    Amdoxovir

    go.drugbank.com/drugs/DB06619
    Investigational

    Synonyms: beta-D-2,6-Diaminopurine-dioxolaneCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  2. Drug

    ARG201

    go.drugbank.com/drugs/DB06621
    Experimental

    ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc). … This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma)

  3. Drug

    Vipadenant

    go.drugbank.com/drugs/DB06625
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Zibotentan

    go.drugbank.com/drugs/DB06629
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

    Categories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 4-AP, 4-Aminopyridine
  7. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of

    Products: XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 4 ADET, XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET
  8. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. … [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra.

    Products: İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (3 ADET), İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (1 ADET)
  9. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

    Categories: Heterocyclic Compounds, 1-Ring, Receptors, Neurokinin-2, antagonists & inhibitors
  10. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.